Singapore, 15 June 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that Dr Carl Firth, Chief Executive Officer and Founder of ASLAN, will be speaking at the Deloitte Taiwan Biotech Seminars organised by Deloitte & Touche Taiwan. The first seminar will take place on 22 June 2016 at the Grand Victoria Hotel in Taipei, Taiwan.
Dr Firth will join industry experts and analysts at the seminar, which will focus on drug valuation. He will deliver a presentation titled “New drug valuation cases in various development phases” at 3:00pm, sharing experience and insights from the perspective of a leading regional biotechnology company.
Dr Firth will also speak at another session scheduled for 13 July 2016 covering the themes of mergers and acquisitions, private placement and international licensing.
The Deloitte Taiwan Biotech seminar series will examine trends in drug valuation and partnering deals within the biopharmaceutical sector in Taiwan, as well as explore case studies of successful Taiwanese biotech companies.
